

PRESS RELEASE
26 February 2010



New number of shares and votes in BioInvent International AB (publ)

Lund, 26 February 2010. BioInvent International AB (publ) (OMXS: BINV) today announced that the company's total number of shares as per 26 February 2010 amounts to 61,095,689 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from an issue of 5,434,800 shares under BioInvent's directed new share issue that was announced on 14 January 2010.

-- END --

Notes to Editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, Daiichi Sankyo, ImmunoGen, Mitsubishi Tanabe, OrbusNeich, UCB and XOMA. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: svein.mathisen@bioinvent.com

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: cristina.glad@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

BioInvent publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on 26 February 2010 at 9.00 a.m. CET.